CareLit · DOI-Nachweis · Pneumologie
Patients with severe eosinophilic asthma benefit from the treatment with Anti-IL-5 Reslizumab – a real life study from Austria
DOI 10.1055/s-0039-1678048
Bibliografische Angaben
Nachweis in CareLit
Autor:innenK Marth, A Renner, K Patocka, W Pohl
ZeitschriftPneumologie
AusgabeS 01 S 01/2019
Jahrgang / SeitenJg. 73
Kernaussage aus der Literatur
Abstract-Vorschau
Patients with severe eosinophilic asthma benefit from the treatment with Anti-IL-5 Reslizumab – a real life study from Austria
Zitieren
Zitierempfehlung
K Marth, A Renner, K Patocka, W Pohl (2019) Patients with severe eosinophilic asthma benefit from the treatment with Anti-IL-5 Reslizumab – a real life study from Austria. Pneumologie, 73 (S 01 S 01). https://doi.org/10.1055/s-0039-1678048
Mit CareLit weiterarbeiten